Piper Sandler Starts InspireMD (NSPR) at Overweight

Piper Sandler analyst Adam Maeder initiates coverage on InspireMD (NASDAQ: NSPR) with a Overweight rating and a price target of $3.00.

The analyst comments "We are initiating coverage of InspireMD (Nasdaq: NSPR) with an Overweight rating and $3.00 PT. NSPR’s CGuard platform is a differentiated stent technology for the treatment of carotid artery disease. CGuard is available in several OUS geographies and is currently being studied in a U.S. pivotal trial (data expected in 2H: 2024). While U.S. approval/launch represents the key milestone in the coming years, we expect to see solid OUS uptake in the interim. Additionally, we see several other catalysts to drive shareholder value, namely launch of the company’s TCAR (transcarotid artery revascularization) device called SwitchGuard in 2025E. We encourage investors to take a closer look at this micro-cap name with the potential for meaningful value creation over the medium to long-term."

For an analyst ratings summary and ratings history on InspireMD click here. For more ratings news on InspireMD click here.

Shares of InspireMD closed at $1.69 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS
• UBS Reiterates Buy Rating on Hilton Worldwide (HLT)